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Abstract 
The Hanahan and Weinberg “Hallmarks of Cancer” papers provide a useful structure 
for considering the various mechanisms driving cancer progression, and the same 
might be useful for wound healing studies.   In this Review we highlight how tissue 
repair and cancer share cellular and molecular processes that are regulated in a 
wound but mis-regulated in cancer. From sustained proliferative signalling and the 
activation of invasion and angiogenesis to the promoting role of inflammation, there 
are many obvious parallels through which one process can inform the other. For 
some hallmarks, the parallels are more obscure.  We propose some new prospective 
hallmarks that might apply to both cancer and wound healing, and discuss how 
wounding, as in biopsy and surgery, might impact on cancer in the clinic. 
 
Introduction and background 
 
For over a century it has been considered that tumours appear to behave like 
wounds that fail to heal (1-4). In recent years it has become clear that there are 
many cellular and molecular parallels indicating multiple shared mechanisms that 
differ only in their being well-regulated during healing of a wound and dysregulated 
during cancer growth and metastasis (5, 6). Whereas acute wound repair normally 
has a resolution phase, tumours behave more like a chronic wound, which has no 
resolution phase. Because of these parallels, the genomic datasets and mechanistic 
findings gathered from studying wound healing may provide us with potential 
insights into the processes that are involved in tumorigenesis and vice versa.  
 
Hanahan and Weinberg’s original and subsequently revised and expanded 
“Hallmarks of Cancer” papers (7, 8) highlight the key mechanisms that appear to 
underpin all cancers.  In this Review we propose that many of these “hallmarks” and 
“enabling characteristics” may also be shared by those mechanisms that underpin 
healing wounds (Fig. 1).  What might be a necessary and precisely activated 
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mechanism for tissue repair is mirrored by dysregulation and failure to attenuate in 
a growing cancer.  This way of thinking may elucidate the parallels between these 
two processes and suggest ways in which these research disciplines might learn from 
one another.  We discuss which of the hallmarks most clearly extrapolate from 
cancers to wounds and those that are less clearly true for both (Fig. 2).  We also 
speculate on additional shared parallels to be considered prospective “hallmarks” or 
“enabling characterists”, and discuss what happens when cancers meet wounds in 
the clinic, such as during biopsy and surgery. 
 
Hallmarks and Enabling Characteristics where there are the clearest parallels: 
Hallmark 1: Sustaining proliferative signalling 
 
Many early studies of cancer focussed on this hallmark because, naturally, without 
cell proliferation, a cancer cannot grow.  Indeed, mutations that affect some key 
oncoproteins (such as Ras and Raf) result in either constitutive activation or failure 
of normal negative-feedback mechanisms, both of which can drive uncontrolled cell 
proliferation without the need for extracellular mitogenic stimuli (9).  Tissue 
damage, by contrast, leads to at least some tissue loss, and generally these missing 
cells need to be replaced as part of the repair process.  
 
 
Cell proliferation during wound repair is restricted to a zone behind the leading 
edge 
In a cancer scenario, cell proliferation can appear haphazard and disorganised, but 
wounding triggers a more coordinated and synchronised proliferative response.  
Classic studies of repair described proliferative zones behind the migrating 
epidermal leading edge (10, 11) . More recent investigations of mouse wounds have 
refined this proliferative zone and shown that it arises several hours after wounding 
and persists for several days;  whilst the proliferative zone is indeed behind the 
immediate leading edge, it can be dynamic and encroach into the zone of migration 
(12, 13) . Once the epidermal wound edges have met and migration ceases, cell 
proliferation spreads into the just-sealed central zone (13). Whilst an inability to 
proliferate is incompatible with repair of large skin lesions, cell division does not 
necessarily drive re-epithelialisation; indeed, tissues that do not divide, for example, 
the epidermis of embryonic Drosophila melanogaster, are perfectly capable of 
healing a small wound (14).  Moreover, inhibiting cell division in murine skin wounds 
with mitomycin c delays but does not prevent wound re-epithelialisation (12).  
 
 
What are the signals for initiating and stopping wound proliferation? 
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Simple in vitro scratch wound assays suggest that cell division is contact-inhibited in 
a confluent, intact sheet of cells, and this inhibition is released upon wounding (15, 
16). This release from contact inhibition might be sensed, in part, by the stretch 
receptor, piezo, which reports tension changes through calcium-dependent 
phosphorylation of extracellular signal–regulated kinases 1 and 2 (ERK1/2), leading 
to cyclin B transcription, which is necessary to drive mitosis.  This change in tissue 
mechanics will be sensed by cells experiencing reduced density as migration begins 
(17).  However, classic laminar flow scratch wound studies have shown that at least 
some of the cell division at a cut edge is driven by increased exposure to growth 
signals in the media (18). We know some of the mitogenic signals that drive 
epidermal wound proliferation in vivo.  For example, fibroblast growth factor 7 
[FGF7, also known as keratinocyte growth factor (KGF)] is strongly stimulated by 
dermal fibroblasts in a skin wound (19), and blocking the epidermal response to this 
signal by expressing a dominant negative FGF2 receptor largely prevents cell 
divisions in the advancing wound epidermis and leads to impaired wound re-
epithelialisation (20). Other important epidermal wound growth factor signals 
include epidermal growth factor (EGF) and transforming growth factor alpha (TGFα) 
(21), both of which are delivered to the wound largely through the degranulation of 
platelets and infiltrating macrophages, and hepactocyte growth factor (HGF), which 
is produced by the advancing wound edge epithelium thus acting as an autocrine 
signal (22). 
 
Some of these proliferation signals are present at the wound from the start, yet the 
surge in proliferation is not immediate.  One early indication of epidermal 
responsiveness conserved from flies to mammals may be an increase in and nuclear 
translocation of immediate early transcription factors including c-Fos/c-Jun and Egr1 
(23-25)  within hours  of wounding.  However, access to the DNA by these immediate 
early transcription factors will be dependent on the epigenetic status of target genes 
in these cells.  At least some of the later activated genes have silencing histone 
methylation marks deposited by the polycomb family of epigenetic regulators. Upon 
wounding the polycombs are repressed and the suppressive marks removed, 
enabling the previously-silenced genes, including that encoding EGFR, to be 
transcriptionally activated (26).  It is tempting to speculate that at least some of 
these wound-induced genes that are first epigenetically un-silenced before they can 
be transcribed, are those that drive key cancer associated mechanisms including 
proliferation and migration, and thus need failsafe regulation. 
 
Many epidermal wound mitogens will naturally disappear as platelets are cleared 
and the inflammatory response resolves, but very likely there are also additional 
active mechanisms that shut down epidermal cell proliferation in the wound 
epidermis as closure is achieved. These will include the very same contact inhibition 
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cues whose release in part drove the initial proliferative surge, as wound edge cells 
now re-establish contacts with their opposite partners (17). Such mechanical cues 
are again detected by mechanoreceptors including piezo, in a process that clearly 
fails to operate properly in a growing cancer (reviewed in (27)). 
 
 
Hallmark 2: Activation of invasion (and metastasis) 
 
Generally, cancers kill when they become invasive and metastasise, and so this has 
become one of the most keenly investigated of the Hallmarks by cancer researchers.   
During wound closure, the process of re-epithelialisation bears considerable 
resemblance to those processes that occur in the early migratory stages of 
carcinoma invasion.   
 
Mechanisms of epithelial migration and partial EMT shared by wounds and 
invasive cancers 
Several hundred genes are switched on in the advancing epidermal wound edge cells 
and many of these are also part of the gene signature(s) of invasive carcinomas 
(Reviewed in (28)).  For a good number of these genes we still don’t know their 
precise function in the repair process but others have characterised roles in transient 
tethering, or proteolysis, or loosening of cell:cell junctions. 
 
The invading fronts of a carcinoma usually comprise small clusters of outgrowing 
cells, and the advancing wound epidermal tongue is similarly pared down to only 
one or two cell layers at the advancing tip.  Wound re-epithelialisation requires 
leading edge basal keratinocytes and all follower cells to leave their usual basement 
membrane (BM) substratum and migrate onto and across a wound provisional 
matrix.  This transition requires an alteration in the integrin expression profile to 
accommodate the changing matrix and enable cells to make transient adhesions for 
forward migration. To migrate from the basement membrane, cells switch off the 
hemidesmosomal α6β4 integrins and upregulate several others not normally 
expressed in unwounded skin; these new integrins are essential for migration across 
the new provisional wound matrix as revealed by wounding of knockout (KO) mice 
for β1 integrin in epidermal cells in which re-epithelialisation is retarded (29). Whilst 
integrin expression is generally confined to the basal layer in unwounded skin, in the 
advancing wound edge, all epidermal cell layers express them (30) , suggesting that 
all cells are active migrators; indeed, recent live imaging studies in repairing murine 
wounds indicate that there is cell shuffling between these layers and active 
participation in the migration process by both suprabasal and basal cells (12).  A 
recent study indicates how one migration specific cell:cell and cell:matrix adhesion 
molecule, L1CAM, appears to be necessary and sufficient in both tissue repair and 
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cancer scenarios in the gut, being produced at colitis lesion sites and wherever 
colorectal cancer cells are metastasising along the basement membrane of nearby 
blood vessels (31). 
 
All adhesion mediated traction-based cell migrations require regulation of a cell’s 
cytoskeleton - largely actin and microtubular – achieved through the Rho GEF and 
GAP regulation of Rho small GTPase switches which, in turn, control when and 
where in a cell the actin-rich machineries of filopodia, lamellipodia and contractile 
stress fibres assemble (reviewed in (32)).  In this regard several studies have shown 
how Rho family small GTPases are absolutely required for wound re-epithelialisation 
(14),  and in many cancers Rhos and their regulators are mutated or mis-regulated in 
other ways (33). 
 
It is generally believed that carcinoma cell invasion involves reversion via a 
developmental programme whereby epithelial cells can convert, at least partially, 
towards a mesenchymal cell phenotype, and then back to epithelial, once migration 
is complete. This epithelial-to-mesenchymal transition (EMT, and the converse, MET)  
occurs partially or fully to enable cells to migrate either as a loosely adherent 
collective or as individual cells (34). Frequently E-cadherin,  the linchpin component 
of adherens junctions linking epithelial cells together, is dysregulated in human 
carcinomas (35). Both basal and suprabasal layers of an advancing wound epidermis 
also exhibit considerable loosening of adhesions between neighbours and these 
junctional changes extend many tens of cells back from the leading edge.  It appears 
that high levels of the EphrinB1 ligand, and thus activation of several Eph receptor 
sub-types, may lead to reduced components of both tight and adherens junctions 
leaving epidermal cells more loosely linked to one another by modified desmosomal 
junctions; this loosening of junctions between cells then provides space for shuffling 
forward of cells within the advancing epidermal wound front (36). In developmental 
biology and in cancer it is believed that EMT/MET is regulated by a series of 
transcription factors including Snail, Slug and Twist (Reviewed in (34, 37)) but in 
wound repair, whilst there is evidence for  involvement of at least Slug in some 
aspects of re-epithelialisation (38, 39), this remains a somewhat understudied area 
of research. 
 
 
Escaping the basement membrane for both wound-edge and cancer cells 
 
As discussed above, the wound edge epidermis must migrate across a denuded 
wound surface where BM is missing.  This new substratum requires epidermal cells 
to first re-equip with the appropriate integrin matrix receptors (see above), and, in 
order for the wound tongue to cut a pathway between scab and healthy wound 
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granulation tissue, it also needs to upregulate several proteases, in particular, MMP1 
which may facilitate integrin:matrix adhesion dynamics by locally cleaving various 
extracellular matrix (ECM) and ECM-associated proteins (Reviewed (40)). 
 
These steps have parallels in all skin cancers during early invasive events where a 
rate limiting step is breakdown of the BM barrier that separates epidermal from 
underlying connective tissue.  Studies in zebrafish indicate that small, naturally 
occurring holes in the BM act as opportunistic portals for immune cells to access the 
epidermis for surveillance purposes, and these routeways also allow immune cells to 
traverse the BM in response to damage attractant signals released by pre-neoplastic 
cancer cells (41).  At later stages, cancer associated fibroblasts (CAFs) have been 
shown in ex vivo models to stretch and soften small regions of the BM in advance of 
cancer cell invasion (42), and subsequently, the BM beneath a growing clone of 
cancer cells becomes locally eroded by invadopodia delivered MMPs which breach 
the barrier and enable full blown cancer invasion  (41, 43). 
 
 
Association of the invasive front with other cell types 
In recent years it has become clear that invasive cancer cells can be supported in 
their migration by other cell lineages in the cancer microenvironment. CAFs tunnel 
through matrix, apparently leading the way for invasive cancer cells (44). 
Macrophages, similarly, co-migrate with invading breast cancer cells (45), as well as 
having other roles in cancer progression (see next section).  Whether similar co-
migratory efforts are important during wound repair has not been carefully studied 
but certainly during Drosophila wound re-epithelialisation macrophages are 
attracted to and associate with the advancing epidermal wound margin (46).  
 
 
Hallmark 3: Tumour- and repair-promoting inflammation  
 
It has long been apparent from patient studies that several cancers are a  
consequence of long term, chronic inflammation (47), and that the presence and 
phenotypic state of inflammatory cells within different cancer types can significantly 
alter prognostic outcome (48).  And yet, inflammation was not one of the original 
Cancer Hallmarks, but rather, was added to the second, revised Hanahan and 
Weinberg listing as an Enabling Characteristic.   
 
Intravital imaging studies in mice have shown the involvement of macrophages in 
tumour metastasis, where they help shuttle cancer cells from the primary tumour to 
nearby vessels from where they  then disperse via the circulation to secondary sites 
(48). These studies have revealed a mutually supportive paracrine loop with cancer 
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cell synthesized CSF-1 and macrophage-derived EGF together guiding the directional 
movement of both cell lineages towards local vessels (49, 50). There is increasing 
evidence, that neutrophils too can play a metastasis-enhancing role at the cancer 
site (51). At much earlier stages of cancer initiation, which are difficult to study in 
mice, researchers have turned to live imaging studies in translucent zebrafish which 
show how surveillance by both neutrophils and macrophages can rapidly detect 
abnormal pre-neoplastic cells from as early as the single cell stage and remain with 
these growing clones, supplying them with trophic signals, and making the early 
cancer micro-environment resemble a chronic wound (52-54). 
 
Some attractants drawing inflammatory cells to wounds are also attractants for 
cancer 
Wounding induces a rapid calcium flash in leading edge epidermal cells that spreads 
across the wounded epithelium as a wave, as shown in studies of worms, flies and 
fish (55-58). This calcium signal activates the NADPH oxidase (NOX),  Duox to 
generate hydrogen peroxide (H2O2) (58) which appears to be a key damage 
attractant drawing inflammatory cells to wounds, at least in flies and fish (59, 60). In 
mammalian tissues, particularly those with a non-mucosal epithelium, we might 
speculate that other NOXes play similar functions.   
 
Just as hydrogen peroxide acts as an early damage signal responsible for drawing 
immune cells to wounds, it has a similar function in recruitment of inflammatory 
cells to pre-neoplastic cells as they first arise in tissues; these “abnormal” cells, and 
their immediate neighbours, release hydrogen peroxide pulses that appear to draw 
innate immune cells to them; that this is a necessary attractant is shown by blocking 
the wet epithelium NOX, called DUOX, in zebrafish larval tissues which “blinds” 
immune cells to growing clones of pre-cancer cells (53). Other damage attractants, 
including HMGB1, appear also to draw leukocytes to both acute wound and to 
cancer cells (61-63) and studies in zebrafish have shown that various chemokines, 
including those binding CXCR2, act as attractants for neutrophils to wounds and also 
to clones of pre-neoplastic cancer cells (52, 64). 
 
Inflammatory cells deliver trophic and other signals to both wound and cancer cells 
The zebrafish studies described above show innate immune cells have the capacity 
to kill and engulf pre-neoplastic cells; generally, however they are instead subverted 
into nurturing them as indicated by genetic knockdown studies where depletion of 
leukocytes prevents further pre-neoplastic growth (52, 53, 65). 
 
Interestingly, although macrophages are abundant at the wound site, they are not 
always essential for wound healing, as indicated by studies of embryo healing which 
is effective even before leukocytic lineages first appear in tissues (66). Furthermore, 
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mice null for the leukocyte switching, ets-family transcription factor, PU.1, which 
lack all innate immune cell lineages, are still capable of efficient wound repair up 
until neonatal stages; these wounds, without an inflammatory response, not only 
heal but do so without a scar, suggesting that fibrosis is triggered by signals from 
inflammatory cells (67), and see later. However, adult tissue repair does seem to 
depend on macrophages for efficient wound healing. Transient depletion of 
macrophages with Diphtheria Toxin in mice results in wound healing deficiencies 
that vary according to which phase of the repair process macrophage killing is  
targeted: early macrophage depletion results in impaired re-epithelialisation, 
reduction of wound granulation tissue and eventually decreased scar size, whereas 
killing of macrophages at later stages results in failure of granulation tissue 
maturation and contraction and eventually leads to wound haemorrhaging (68), 
suggesting a role in wound angiogenesis (see later).  
 
Genetic depletion of leukocytes in various models at various stages in cancer 
progression suggests a similar “supportive” role for neutrophils and macrophages 
towards cancer cells (69-75). Indeed, several of the key growth factor signals 
delivered to a wound by macrophages with established regulatory roles in repair, 
also have related functions in cancer progression and vice versa. 
 
Transforming growth factor betas, (TGF-ßs) 1 and 2, for example,  are delivered to 
the wound both through degranulation of platelets and through expression by 
macrophages, and have multiple functions, influencing several cell lineages within 
the wound granulation tissue including immune cells and wound fibroblasts which 
may drive aberrant collagen deposition resulting in a wound scar, reviewed in  (76). 
TGF-ß1 has more complex roles in cancer, being both positively and negatively 
associated with tumour progression. Initially TGF-ß1 was discovered as a tumour 
suppressor, with mutations in TGFβR1 and 2 and the downstream regulators SMAD1 
and SMAD4, indicating a suppressive role for TGF-ß signalling. However, 
overexpression of TGF-ß1 has also been linked to multiple cancers including breast, 
lung, colon, oesophageal and pancreatic cancer, and correlates with poor prognostic 
outcome. This may be, in part, because of its capacity to drive tumour immune 
evasion (77). Frequently it seems, in early stage cancers a high level of TGF-ß is 
prognostically favourable, whereas in late stages, TGF-ß in the microenvironment 
promotes tumour growth, leading to the TGF-ß paradox (78-81). 
 
The TGFβ related growth factor, activin, also has both pro-tumurigenic activity and 
considerable effects in a wound repair scenario.  It seems that both of these 
influences may be mediated by activin’s activity on inflammatory cells (82). 
 
The platelet-derived growth factors (PDGFs)  are another family of growth signals 
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associated with inflammation and with strong links to cancer; many malignancies are 
associated with overactivity of PDGF signalling (83), and similarly they appear to 
have multiple and complex activities, both positive and negative, during tissue repair 
(21). Ectopic expression of PDGF-B in murine non-healing “diabetic” wounds leads to 
faster wound closure (84) but PDGF released at the wound site by macrophages has 
been shown to trigger production of osteopontin in wound fibroblasts which, in turn, 
leads to scar collagen deposition (85). 
 
 
Hallmark 4: Angiogenesis 
 
It is generally considered that tumours cannot grow beyond 1mm in diameter 
without recruiting their own vascular supply, largely from pre-existing vessels in the 
vicinity of the growing tumour, and as a consequence there has been considerable 
research, led by initial studies from the Folkman lab (86), into what are the tumour-
derived angiogenic signals and how might they be dampened to block this rate 
limiting step in cancer progression.  
 
Cancer and wound vessels share the characteristics of being hyper-branched and 
leaky 
Cancer vessels are visibly different from normal tissue vasculature.  Perhaps due to 
overexpression of various angiogenic factors they tend to be tortuous, disorganised 
and leaky and remain so throughout cancer progression, reviewed in (87).  Wound 
angiogenesis also initially consists of a complex intertwining network of leaky 
capillaries, but this is only a transient condition and they rapidly acquire a pericyte 
layer and become fully patent after several days (88).  Angiogenesis at sites of tissue 
repair appears to be similarly rate limiting as it is for a growing cancer, and its failure 
is associated with chronic non-healing wounds, whilst an inability to resolve wound 
vessels has been linked to overgrowing keloid scars (89-91) reviewed in (92).  
 
Inflammatory cells play pivotal roles in both developmental and wound 
angiogenesis 
For tumour vessel growth it is believed that the “angiogenic switch” is a complex 
interplay involving reduced levels of  a portfolio of poorly characterised angiogenesis 
inhibitors, complemented by a new local source of pro-angiogenic signals, primarily 
thrombospondin and vascular endothelial growth factor (VEGF) (93).  At least some 
of this pro-angiogenic signalling is believed to be a consequence of inflammation 
(94). In the initial laying down of vessels in embryonic tissues, macrophages are not 
required for the earliest stages of vessel sprouting per se, suggesting that other 
guidance cues are at play, but they do have a role in subsequent remodelling and 
anastomosing of developing vessels (95). At a site of tissue damage, evidence 
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indicates that macrophages are essential for all aspects of wound angiogenesis.  This 
may be in part because of their early interactions with neutrophils (not present in 
the early embryo), which generally arrive at the damage site before macrophages 
and are initially seen associated with vessel tips. Neutrophils appear to be inhibitory 
to vessel sprouting (perhaps via secretion of truncated VEGF receptors); 
macrophages release this inhibitory signal by dislodging the early recruited 
neutrophils as well as subsequently being a local source of pro-angiogenic VEGF (88). 
 
 
Resolution of angiogenesis 
During embryogenesis there are several transient vascular networks that must 
eventually resolve. This developmental pruning is partially mediated by Wnt7a 
signals delivered by macrophages, which likely act by countering VEGF angiogenesis-
promoting signals (96, 97). As a cancer therapeutic, several anti-VEGF drugs are 
approved, but while they have had some success, particularly in combination 
therapies, they are not the magic cancer blockers initially hoped for; rather, they 
may excessively prune tumour vessels leading to local hypoxia, which can trigger 
ectopic early metastatic spread (98, 99).  In a wound scenario, late-stage 
macrophages switch from a pro-inflammatory phenotype and have a second, 
contrasting role, this time driving vessel regression, but unlike in development, Wnt7 
signalling seems not to mediate this vessel resolving instruction (88). 
 
 
 
Hallmarks 5 and 6: Resisting cell death and avoiding immune cell destruction 
 
These two Hallmarks may have different underlying mechanisms in a cancer scenario 
but we think they can be considered as a continuum for the purposes of tissue repair 
since the signals for killing healthy cells within a healing wound come largely from 
the “friendly fire” of recruited inflammatory cells. 
 
At any site of malignant cancer growth, there will be numerous physiological stresses 
that, in healthy tissues, would trigger apoptosis; these include the signalling 
imbalances associated with sustained proliferative signalling, which, in turn, can lead 
to DNA damage, as can the cell damaging signals from inflammatory cells; other 
stresses will be the hypoxic and reduced nutrient conditions that are a consequence 
of a tissue outgrowing its angiogenic supply (see earlier), not to mention cancer 
therapeutics including chemotherapy and radiotherapy.  And yet the apoptotic 
switches appear subdued, or even shut down in cancer cells (100).  This capacity to 
ignore pro-apoptotic cues is achieved in numerous ways, including, most commonly, 
loss of the tumour suppressor p53 which has critical DNA damage sensing functions 
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(reviewed in (101)), or upregulation of anti-apoptotic signals including those of the 
Bcl-2 family (reviewed in (102)). Rather little research has been undertaken to 
investigate these apoptotic-regulator pathways during tissue repair, but there is 
some indication that p53 plays a role in wound re-epithelialisation and indeed that 
its transient shut down can accelerate normal repair (103, 104).  
 
Cancer cells must also avoid surveillance and destruction by both innate and 
adaptive arms of the host immune system. One of the key mechanisms whereby 
cancer cells “evade immune cell destruction” is by “masking” themselves through 
upregulation of inhibitory checkpoint molecules, and this strategy has been recently 
highlighted as a therapeutic Achilles heel with new anti-PD1 and anti-CTLA4 antibody 
treatments which expose aberrant cells to T-cell killing. (Reviewed in (105)). In a 
wound repair scenario there is now good evidence that some elements of an 
adaptive immune response are activated alongside the more fully studied wound 
inflammatory response, namely a local sentinel subpopulation of γδT (106) and a 
transient influx of T-regs (107); both of these contribute to healing, and are 
nurturing to host repairing cells.   However, the innate immune response is “clumsy” 
and non-specific in its killing strategies (see below).  
 
Several tissue resilience pathways are activated soon after tissue damage 
 
As described above, any tissue damage will trigger a rapid inflammatory response in 
order to counter potential infection.  Inflammatory cells, particularly the early 
recruited neutrophils, release microbiocidal factors including reactive oxygen species 
(ROS) to eliminate pathogens but of course these will also be toxic to host tissues. To 
counter these inflammatory “stresses” organisms have evolved a battery of 
cytoprotective mechanisms to limit collateral damage.  Studies in mammalian and 
Drosophila wound models have uncovered several complementary signalling 
pathways that enable host tissues in the wound vicinity to survive in this hostile 
environment.  One of these, Nrf2, is rapidly activated downstream of Ca++ signals in a 
rim of epidermal cells at the margin of the wound and this leads to activation of a 
number of ROS sequestering enzymes which “shield” cells and permit their survival 
where they otherwise would die (108, 109). In parallel with the ROS sequestering 
“shield” downstream of Nrf2 signalling, DNA and other repair machineries are also 
produced, including for example GADD45, which appears to enable more effective 
access to damaged DNA and is produced as a consequence of inflammation, since in 
flies and mice devoid of inflammation, GADD45 levels did not increase in the wound 
epidermis (108, 110). Ectopic expression of GADD45 in Drosophila epidermis is 
sufficient to protect it from UV-induced killing even in the absence of a wound (108). 
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Hallmark 7: Deregulating Cellular Energetics 
 
This is one of the newly highlighted Cancer Hallmarks although its underpinning 
research began almost a century ago when Warburg first described how cancer cells 
tend to utilise glycolysis rather than oxidative phosphorylation to fuel their activities 
(111, 112). Recent studies in Drosophila show how lactate dehydrogenase (LDH), a 
key enzyme in Warburg effect metabolism, is necessary and sufficient for the switch 
from hyperplasia to neoplasia in skin cancer models (113). Indeed, PET scanning in 
the clinic takes advantage of this phenomenon since cancer cell glycolysis is hugely 
more demanding of radioactively tagged glucose than healthy cells and so highlights 
cancer cell location in tissues (114).  The altered metabolic cancer “signature” can 
even be used to guide a surgeon’s “iKnife” as they excise the margins of a tumour 
(115).  
 
Metabolism has only recently begun to be considered anything more than a niche 
topic by wound healing researchers, but new findings suggest it may be a key player 
in repair, just as in cancer.  In the 1960s Thomas Hunt and colleagues revealed high 
levels of lactate in healing wounds and speculated that several cell lineages switch to 
a glycolytic pathway and that this might be key to some elements of the repair 
process (116). Gene expression studies in the regenerating Xenopus tadpole show 
that many genes linked to glycolytic metabolism are locally induced here also (117) .  
More recent single cell transcriptomic analysis of mouse skin wounding indicates a 
dramatic alteration in expression of metabolism-associated genes with those 
associated with reduced oxidative phosphorylation and complementary active 
glycolysis-associated genes in sub-populations of wound edge cells (118).  Studies in 
the regenerating zebrafish heart also show evidence for cardiomyocytes in the 
border zone at the edge of  a wound reprogramming their metabolism, suggesting 
that metabolic plasticity might explain why fish cardiac tissues can repair so much 
more efficiently than their mammalian  equivalents, because blockade of this 
metabolic switch significantly impairs fish heart repair (119). 
 
Inflammation is known to be key in both cancer and wound healing (see above), and 
it may be that inflammatory cells, in part, have these pivotal roles by being the key 
sensors of altered microenviromental conditions, for example hypoxia, as well as 
being the mediators of changes to metabolic signalling in other cells, (120). 
 
Cancer Hallmarks that might not be shared by repairing tissues 
 
It would be disingenuous to presume that all Cancer Hallmarks have likely parallels in 
wound repair, although equally naive to argue that they absolutely do not.  
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However, we think that for three of the Hallmarks/Enabling Characteristics for 
Cancer, the links to wound repair are likely to be slim. 
 
Evading Growth Suppressors and Enabling Replicative Immortality 
 
These two Hallmarks of Cancer have no immediately obvious parallels in the tissue 
repair response.  The closest that a wound edge cell comes to “evading growth 
suppressors”  is when some of those signalling pathways that enable proliferation 
and migration are transiently epigenetically “unsilenced” as discussed above, but 
when the wound has repaired they will be epigenetically “silenced” again (26) in 
ways that clearly fail to occur in a progressing cancer.   
 
Similarly, there is no evidence that migrating wound edge cells become immortal. On 
the contrary, epidermal and fibroblast cells at the wound margin may become 
senescent and recent studies suggest that the senescence-associated secreted 
phenotype (SASP) includes signals that are beneficial to repair (121). As a counter to 
this, and in support of the observation that younger tissues repair better than older 
tissues, is the finding that mice with “hyper-long” telomeres exhibit faster skin 
healing than their WT sibs (122). 
 
 
Genomic Instability and Mutation 
 
Here, again, it doesn’t seem likely that this Enabling Characteristic of cancer has any 
direct equivalent in a tissue repair scenario unless one considers chronic wounds 
with their persistent inflammation, potential excessive viral load, and exposure to 
unprotected UV damage; all of these may result in secondary mutations leading to 
neoplastic lesions in this vulnerable, exposed tissue, as, for example,  occurs in 
Marjolin’s ulcers at the margins of venous leg ulcers (123).  In the context of cell 
abnormalities in cancer, and possibly of broader relevance to general tissue repair 
than currently understood, are observations in larval Drosophila where wound edge 
epithelial cells fuse and become syncytial, although this is not linked to mutation or 
genomic instability (124).  
 
Shared Hallmarks that are not bona fide Cancer Hallmarks (yet) 
 
There have always been discussions about what “Cancer Hallmarks” are missing or 
might be coming in the next Hanahan and Weinberg update, and we have some 
suggestions below that are inspired, in part, because they have recently become 
extremely popular topics for cancer research, and moreover, are becoming hot 
topics in tissue repair research too.  All three of these potential prospective 
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Hallmarks could be considered as either upstream or downstream of the established 
enabling characteristic of inflammation that promotes both tumours and wound 
healing. 
 
Microbiome alterations  
 
From birth—and possibly earlier—all external-facing human epithelial tissues, 
including the skin and gut, are colonised by bacteria that eventually establish 
homeostasis and symbiotically influence the local immune cell repertoire and 
systemic immunity (125). Disturbances of the microbiota, known as dysbiosis, have 
been implicated directly and indirectly in cancer development with the presumption 
that such changes will likely impact on local inflammation to drive cancer initiation 
and progression ((126) and above).  In the gut, a failure to control pathogenic 
microorganisms frequently leads to dysregulated inflammation and tissue damage, 
leading to disorders such as Crohn’s or inflammatory bowel disease, both of which 
considerably increase the risk of bowel cancer (127).  More direct links between 
alterations in microbiome leading to cancer include bacterial infections, such as 
infection with Heliobacter pylori, which is associated with a large proportion of all 
stomach cancers (128), and it is now clear that many other cancers have associated 
microbiome signatures (129). More directly, it has been demonstrated that injecting 
bacterial toxins into gut organoids drives a signature of oncogenic mutations 
common to human colorectal cancer even in the absence of any inflammatory cell 
mediators (130).  
 
Whereas alterations in the microbiome of a tissue are generally considered to be 
potential activators rather than inhibitors of cancer progression, there is a classic 
observation reported by William Coley in the early 1900s of some patients with 
inoperable cancers, in which infections leading to fevers occasionally resulted in 
their tumours “melting” away (131). Although the mechanisms underpinning this 
phenomenon are still not entirely clear, loading the bladder with Bacillus Calmette-
Guérin (BCG), an attenuated strain of Mycobacterium bovis, has remained a standard 
treatment for bladder cancer (132). Clearly, an understanding of how infections 
somehow modulate the host immune response to kill cancers is well worthy of 
further research.  
 
That the wound microbiota might influence the efficiency of healing also seems 
plausible because infection of both wild-type and diabetic mice, which have 
impaired healing, tends to retard healing, and antimicrobial treatment rapidly 
reverses this impairment  (133).  However, there is some controversy over whether 
germ-free (GF) animals are more effective healers than colonized animals, or, 
conversely might exhibit reduced healing capacity (134), perhaps through a failure of 
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the activation of Toll-like receptors that are required permissively for some aspect of 
the repair process.  In most reports, it is clear that the inflammatory response is 
dampened in GF animals; for example, one study of GF mice reports that they heal 
their wounds faster, have increased vasculature, and repair with less scarring, which 
might be because of a reduced neutrophilic influx (135). 
 
Advances in high throughput 16S bacterial sequencing have provided the first 
detailed insights into the complexity of the skin microbiome and how it varies 
between individuals and across anatomical sites, and some of the changes that occur 
post wounding (136).  The host wound response has clearly evolved ways to counter 
these dramatic changes in bacterial flora; in instances of  tissue damage where 
bacteria invade a wound site, some of this protective machinery is now coming to 
light, including NOD2, which is an intracellular receptor recognising motifs from both 
gram-positive and gram-negative bacteria.  NOD2 null mice have an altered skin 
microbiome favouring pathogens over commensal species, and this dysbiosis 
becomes exaggerated following wounding leading to severely delayed healing (137). 
Moreover, the dysbiotic microbiome is dominant because mixing of NOD2 null mice 
with WT sibs results in the WT mice “catching” impaired healing (137).  
 
Aberrant matrix deposition 
 
Extracellular matrix defines the mechanical properties of all tissues, and is a key 
element of the cancer microenvironment that can directly impact on prognostic 
outcome of the cancer (138). For example, the presence of perpendicular, cross-
linked and stiffened collagen bundles has been shown to associate with invasive 
regions of breast cancers and to link to worse outcome for patients (139). 
 
Cancer cells may be, in part, responsible for signalling aberrant collagen deposition 
themselves, but equally this will also be driven by inflammatory and other cells in 
the cancer micro-environment.    TGFβ, is a key driver of excessive matrix deposition 
and is highly expressed by macrophages in the most aggressive breast cancer 
subtypes and at sites of increased collagen deposition (140).  Lysyl oxidases (LOX), 
which are rate limiting in cross-linking collagen fibres, are also frequently reported as 
mis-regulated in many tumour types and likely involved in regulation of metastatic 
spread (141).  A crosslinked, stiff matrix encourages integrin clustering and sustained 
PI3K/Akt and ERK signalling which promotes both survival and migration, and 
provides tracks to facilitate invasion away from the primary tumour site (142, 143).  
Indeed, in a mouse model of pancreatic cancer, LOX inhibition suppresses invasion of 
cancer cells and prolongs tumour free survival of these mice (144).  
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A fibrotic environment also provides the ideal pre-metastatic niche for cancer cells 
to home to as revealed by studies of bleomycin-induced lung damage which triggers 
a fibrotic response and favours the seeding of tail vein injected tumour cells in mice 
(145). 
 
In a wound scenario it is clear that inflammation, whilst pivotal and required for 
various aspects of adult healing (see above), is also causal of aberrant collagen 
deposition resulting in a fibrotic wound scar.  In embryonic tissues where leukocytes 
are not yet present, wounds can heal without a scar (66), and PU.1 KO neonatal mice 
lacking all leukocytes also can also repair without fibrosis (67).  Inflammation drives 
fibrosis in wounds via several signalling pathways including TGFβs 1 and 2 which are 
known to trigger collagen and other matrix deposition by wound fibroblasts; 
blocking TGFβ signalling at the wound site has been shown to dampen the fibrotic 
response (146). IL4 activated macrophages at the wound site also drive fibroblast 
expression of the collagen cross-linking enzyme lysyl-hydroxylase 2 which, as in the 
vicinity of a cancer, leads to the stiffened unresolvable collagen of a dermal scar 
(147).   
 
 
Adipocytes – not silent bystanders 
There is now considerable epidemiological evidence indicating a link between 
obesity and several cancer types (148).   During weight gain, adipocytes become 
hypertrophic and eventually many die, which in turn triggers an accumulation of 
phagocytic macrophages which envelope the dying adipocytes and form 
characteristic crown-like structures (CLS) which are phenotypically and 
transcriptionally different from other adipocytes (149). Particularly in hormone-
driven cancers with close proximity to large fat deposits, for example, breast and 
prostate, it seems that positive CLS status is associated with a poor prognostic 
outcome; there is also evidence for systemic endocrine effects on cancers at distant 
sites (150). 
 
Aside from these indirect effects on tumour cells through inflammation and fibrosis, 
adipocytes can also deliver adipokines and other signals that influence tumour cell 
growth, and there is clear evidence, also, of them becoming metabolic slaves to the 
cancer cells.  A recent study of human biopsy material and in vitro co-culture 
indicates how advanced melanomas invade and make direct contact with 
subcutaneous adipocytes which can directly transfer fatty acids to the tumour cells 
(151) and similar has been shown for omental adipocytes “feeding” ovarian cancer 
cells (152) .  In vivo zebrafish studies show how engrafted melanoma cells tend to 
home to subcutaneous sites adjacent to endogenous adipocytes and, as a 
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consequence of taking up extrinsic lipids from these cells, the tumour cells adjust 
their own metabolism and downregulate lipogenesis genes (151).  
  
Obesity has close association with onset of type 2 diabetes, and diabetic individuals 
are known to be much more prone to impaired wound healing, as a consequence of 
neuropathy, poor vascularity and pre-disposition to infection because of chronic high 
levels of blood glucose (153).   In the wound repair community there is new interest 
in a more direct role for adipocytes and their pre-adipocyte precursors.  For 
example, in Drosophila pupae, fat body cells, which are the fly equivalents of 
adipocytes, have been shown to utilise a novel adhesion-independent “swimming” 
motility to home towards and plug a wound, where they also upregulate 
antimicrobial peptides and collaborate with macrophages to clear cell and matrix 
debris (154). In murine wounding studies there is no evidence yet for adipocyte 
migration, but myofibroblasts have been shown to transdifferentiate into adipocytes 
(155) , and adipocyte precursors differentiate into mature adipocytes, and while 
little is known about the mediating signals, these cells appear to contribute to repair 
because blocking their differentiation leads to defects in migration of fibroblasts into 
the wound and to impaired matrix deposition (156). Just as in Drosophila wound 
repair, mammalian adipocytes may also play a role in microbe killing since impaired 
adipogenesis results in increased skin infections (157). 
 
 
Wounding can activate cancer initiation or reawaken dormant cancers 
 
Besides sharing many cell and molecular mechanisms, as discussed in the Hallmarks 
comparisons above, tissue damage and cancer are frequently juxtaposed in the clinic 
since tissue biopsies are the mainstay of screening for and grading various cancers, 
and surgery (and radiotherapy) are still two of the most effective means for curing a 
patient of cancer.  In recent decades a trickle of papers address how cancer biopsy 
and surgery, which by necessity will damage tissues and thus trigger a wound 
inflammatory response, might impact on residual cancer cells.  
 
There have been several clinical studies over the years describing how tissue 
damaging cancer treatments, may locally or systemically influence cancer growth or 
progression to malignancy (28). These local influences have been mirrored in basic 
science studies beginning with the observation that Rous sarcoma injected chicks 
tended to only develop tumours at the site of injection (158), and similarly, 
wounding was needed to trigger tumorigenesis in v-jun transgenic mice (159). 
Subsequently, studies using a variety of animal models, have all shown that wound-
triggered cancer initiation is mediated by inflammation (160-164). In the case of 
melanoma patients there is clear clinical evidence that local tissue damage can 
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exacerbate cancer progression and worsen patient prognosis (164).  Similarly, needle 
biopsies for breast cancer are believed to be a potential activator of cancer 
progression (165).  A further support to the concept that “wounding activates 
cancer” is the fragile skin disease, recessive dystrophic epidermolysis bullosa (RDEB) 
in which patients with mutations in collagen 7, a linker protein between epidermis 
and dermis, suffer from persistent cycles of skin blistering and repair and scarring.  
Because of better infection control these children are now surviving into young 
adulthood but all succumb to multiple, aggressive cutaneous squamous cell 
carcinomas (SCC) as a consequence of the constant wound inflammation and 
infection (166).  
 
 
Conversely, however, for some other cancers, including basal cell carcinoma (BCC), 
tissue damage, and local activation of an inflammatory response, is sometimes 
reported to lead to cancer regression, and is even occasionally used as a therapeutic 
strategy, particularly in elderly patients where surgery is not possible (167).   That 
local wounding might sometimes be inhibitory to cancer progression is supported by 
a study in mice showing that for some xenografted human cancers, the presence of a 
nearby ulcer or ischaemic wound, can lead to inhibition of tumour growth (168). 
 
 
Aside from local influences, tissue damage can also lead to systemic activation of 
cancer growth as has been mostly clearly described for breast cancer where 
reconstructive plastic surgeries are believed to occasionally trigger subsequent 
inflammation-associated “reawakening” of otherwise dormant lung micrometastasis 
(169).   This activation of distant “dormant” T-cell restrained cancers has recently 
been replicated in mice  and shown to be mediated by systemic mobilisation of 
innate immune inflammatory cells, and moreover can be dampened by transient 
treatment with anti-inflammatory drugs (163) . 
 
Clearly more research is needed to understand better which cancers are most likely 
to be exacerbated by wound-triggered inflammation, locally or at a distance, and for 
which the converse might be true, so that cost-benefit judgements can better be 
made in the clinic, and appropriate anti-inflammatory treatments considered 
wherever tissue damaging procedures need to be undertaken on patients. 
 
Lessons from cancer for wound healing and vice versa, now and in the future 
 
For all of the Hallmarks and Enabling Characteristics discussed above, there are 
obvious overlaps in research insights from the cancer and wound healing 
communities that we all must capitalise on. Good examples include our fuller 
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understanding of pro-angiogenic mechanisms which are pivotal in both cancer and 
wound repair, and which will lead towards strategies for improving chronic wound 
healing, as well as for starving a cancer or enhancing the vascular supply of 
chemotherapeutic drugs to the cancer.  Similarly, figuring out precisely how 
inflammation is triggered and how it influences downstream targets and how it too 
can be modulated or re-programmed, will underpin development of important 
therapeutics for both wound healing and cancer.  One clear shared goal here will be 
novel immunomodulatory strategies developed to dampen fibrosis which should be 
beneficial both for reducing extensive scarring, for example in burn victims, and also 
for retarding metastatic spread of several cancers.  In that regard, the antifibrotic 
drug pirfendon, which in part acts to modulate TGFβ signalling, and is already used 
to treat idiopathic pulmonary fibrosis, is proving effective as a blocker of cancer 
associated fibrosis in several mouse models and also appears to make cancers more 
prone to chemotherapy killing (170, 171). 
 
We can see several as yet untapped opportunities where one of our fields could 
learn more from the other.   For each Hallmark there are examples of known wound 
activated pathways that are not yet fully investigated in cancer and vice versa.  For 
example, while prostaglandins are implicated in driving cancer progression, they are 
barely studied in wound healing, and a converse imbalance of research effort is true 
for studies of platelet function in wound clotting and repair, versus in cancer biology.  
And while we are beginning to know about how tissues in the vicinity of wounds 
make themselves “resilient” to a harsh environment, we have yet to extrapolate all 
of this knowledge to develop tools for “switching off” of this same machinery in 
cancer cells which will undoubtedly harness these same protective pathways for 
their own better survival.   
 
One general area of tissue repair that is relatively under-researched and yet would 
clearly offer considerable insight to cancer studies across several Hallmarks, involves 
those mechanisms that lead to shutting down of the repair process.  If we had a 
fuller understanding of the molecular cues underpinning, for example,  how 
epidermal cells stop migrating (and proliferating) once wound edges have met, and 
similar for “shutting down” of all the other aspects of tissue repair, then some of this 
knowledge might offer particularly useful insights into how we might develop better 
“brakes” to stop cancers progressing.  
 
Outside of the classic Hallmark territories there are other potentially fruitful areas 
for crossover.  For example, there has long been an understanding that cutaneous 
innervation may have some signalling role to play in wound repair (172, 173), and 
indeed, innervation is critical for regeneration of limbs in salamanders and fins in fish 
(174), but innervation is not well studied in cancer biology.    As we described above, 
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Folkman and others observed how a tumour, like an aberrantly growing organ, 
draws in a vascular supply, but it is now becoming clear that the growing cancer 
recruits in a source of innervation too (175) and, just as in a wound, this innervation 
could be a source of growth signals and thus a potential target for anti-cancer 
therapeutics also.  And conversely, whilst there is a considerable literature on the 
development of cancer lymphatics because of their being a route for cancer cell 
dissemination (176), only recently have they been investigated in repair scenarios 
with the first studies being in the regenerating heart of zebrafish (177). Nerves and 
lymphatics could both prove to be much more important than currently presumed 
for wound healing and for cancer biology.  
 
Ever growing human genomic datasets will provide the means for further exchange 
of concepts between the cancer and wound healing fields.  Harnessing population 
health approaches in patient datasets will enable analysis of transcriptomic and 
epigenetic parallels (and differences) between repairing wounds and the signatures 
of various cancers at different stages of their progression 
 
These insights together will hopefully guide us towards more shared Hallmarks and 
further opportunities for repurposing drugs that are trialling for cancer to be test 
driven as wound healing therapeutics and vice versa. The flip side of such a 
reciprocal approach, of course, is a consideration that because of the multitude of 
shared mechanisms, any drug that might improve one, might also have unexpected 
consequences on the other. 
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Figure Legends 
Figure 1.  The classic “Hallmarks of Cancer” circle adapted from Hanahan and 
Weinberg (2011) to illustrate parallels between cancer and wound healing.  
Hallmarks and Enabling Characteristics are mirrored in a Wound Healing circle as 
discussed in the text of this Review.  A green tick reflects where parallels are very 
clear, a black cross suggests we see no parallels, and a blue question mark hints that 
there may be parallels.  Three new prospective Enabling characteristics or Hallmarks 
that may fit for both cancer and wound healing sit centrally in red, and all lead 
towards or derive from tumour (and wound) promoting inflammation. 
Figure 2.  How the “Hallmarks” extrapolate to a healing wound.  Here the 
“Hallmarks and Enabling Characteristics” Wound Healing circle with three additional 
prospective Hallmarks, are all mapped onto a schematic of a healing skin wound to 
illustrate how cell migration and proliferation drive re-epithelialisation and how this 
tissue is also dependent on altered cellular energetics, as well as mechanisms to 
avoid immune destruction and resist cell death.  Several “damage” signals, as well as 
those activated by the microbiome and fat cells, trigger an inflammatory response 
which in turn regulates both wound angiogenesis and matrix “scar” deposition. In 
the circle is Galen’s 16th Century Wound Man. 
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